Conclusions
toxicity
Our findings indicated that in patients with RM-NPC, camrelizumab plus apatinib exhibited promising antitumor efficacy and acceptable toxicity. These results support the view that anti-angiogenic drugs combined with immunosuppressants represent a new and promising anti-tumor combination regimen for RM-NPC. To confirm our findings, larger randomized controlled trials are required.